Barclays PLC Buys 158,244 Shares of Savara Inc (NASDAQ:SVRA)

Barclays PLC raised its stake in shares of Savara Inc (NASDAQ:SVRA) by 217.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 231,005 shares of the company’s stock after purchasing an additional 158,244 shares during the period. Barclays PLC owned 0.13% of Savara worth $979,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of SVRA. Choreo LLC bought a new stake in Savara during the 2nd quarter valued at approximately $59,000. DRW Securities LLC acquired a new position in shares of Savara during the second quarter worth approximately $62,000. Principal Financial Group Inc. boosted its position in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Profund Advisors LLC acquired a new stake in shares of Savara in the second quarter worth $105,000. Finally, BNP Paribas Financial Markets increased its position in Savara by 258.9% during the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares during the period. Institutional investors own 87.93% of the company’s stock.

Insider Buying and Selling at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of Savara stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the completion of the transaction, the chief executive officer now owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. The trade was a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Joseph S. Mccracken bought 20,000 shares of Savara stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the acquisition, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 5.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wells Fargo & Company began coverage on shares of Savara in a report on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target for the company. HC Wainwright reduced their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Evercore ISI restated an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.86.

Savara Stock Down 2.5 %

Shares of SVRA opened at $2.72 on Wednesday. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $3.29 and a two-hundred day moving average price of $3.88. The stock has a market cap of $466.80 million, a price-to-earnings ratio of -6.33 and a beta of 0.68. Savara Inc has a 12 month low of $2.60 and a 12 month high of $5.70.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Equities analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.